Clinical Trial Update: A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 first-in-human study of IPH5301, an anti-CD73 antibody, given alone or with chemotherapy and trastuzumab, in patients with advanced solid tumors, is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Endometrial Cancer
• Esophageal Cancer
• Gastric Cancer
• Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• IPH5301 (IPH5301)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Institut Paoli-Calmettes | Conditions: Metastatic Cancer, Metastatic Breast Cancer | Phase 1 | Status: RECRUITING